{"groups":[{"description":"Participants with non-Hodgkin's lymphoma were assigned to Plerixafor PM, Plerixafor AM, and Plerixafor After Chemo treatment arms.","id":"FG000","title":"Non-Hodgkin's Lymphoma (NHL)"},{"description":"Participants with multiple myeloma were assigned to any of the 4 treatment arms.","id":"FG001","title":"Multiple Myeloma (MM)"}],"periods":[{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"Adverse Event"}],"milestones":[{"achievements":[{"comment":"Plerixafor PM=7, Plerixafor AM=6, Low CD34+ Count/Plerixafor PM=0, and Plerixafor After Chemo=1","groupId":"FG000","numSubjects":"14"},{"comment":"Plerixafor PM=12, Plerixafor AM=9, Low CD34+ Count/Plerixafor PM=1, and Plerixafor After Chemo=4","groupId":"FG001","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"comment":"Completed refers to completed all treatment visits.","groupId":"FG000","numSubjects":"14"},{"comment":"Completed refers to completed all treatment visits.","groupId":"FG001","numSubjects":"25"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"0"},{"groupId":"FG001","numSubjects":"1"}],"type":"NOT COMPLETED"}],"title":"Treatment Period"},{"dropWithdraws":[{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"3"}],"type":"Final assessment not done"},{"reasons":[{"groupId":"FG000","numSubjects":"1"},{"groupId":"FG001","numSubjects":"0"}],"type":"Death"}],"milestones":[{"achievements":[{"comment":"Participants who had transplants","groupId":"FG000","numSubjects":"14"},{"comment":"Participants who had transplants. One participant did not complete therapy but had a transplant.","groupId":"FG001","numSubjects":"26"}],"type":"STARTED"},{"achievements":[{"comment":"Follow-up visit 12 months post-transplant","groupId":"FG000","numSubjects":"12"},{"comment":"Follow-up visit 12 months post-transplant","groupId":"FG001","numSubjects":"23"}],"type":"COMPLETED"},{"achievements":[{"groupId":"FG000","numSubjects":"2"},{"groupId":"FG001","numSubjects":"3"}],"type":"NOT COMPLETED"}],"title":"Follow-up Period"}],"preAssignmentDetails":"Forty-four participants were enrolled; four participants never received plerixafor treatment so are excluded from summary tables.","recruitmentDetails":"Patients with NHL or MM eligible for the study were recruited from 5 centers in the United States. The first patient was enrolled (signed informed consent) in April 2004 and the last patient's last study visit was July 2006."}